BioMimetic Therapeutics is a biotech company utilizing recombinant human platelet-derived growth factor (rhPDGF-BB) as its primary technology platform.  This molecule is a synthetic copy of one of the body's principal agents to stimulate and direct healing and regeneration.  The mechanism of action of this platform technology suggests it may be effective in a broad array of musculoskeletal applications, including the repair of bone, ligament, tendon and cartilage. Through the commercialization of this technology, BioMimetic seeks to become the leading company in the field of orthopedic regenerative medicine.